Mosquirix (RTS,S): A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria

Abstract

Spanish

French

Objective:

To summarize and evaluate the literature for Mosquirix (RTS,S) and provide insight into the therapeutic and economic controversies of this novel malaria vaccine candidate.

Data Sources:

A systematic literature search was performed using the terms Mosquirix; RTS.S; malaria; vaccine; and Plasmodium in MEDLINE (1948–November 2011), EMBASE (1980–November 2011), International Pharmaceutical Abstracts (1970-November 2011), Google, and Google Scholar.

Study Selection and Data Extraction:

Clinical trials describing vaccine development, pharmacology, pharmacokinetics, efficacy, and safety were reviewed. For efficacy, clinical trials were reviewed that reported acquisition of malarial disease. Information regarding study design, population, study period, baseline characteristics, clinical outcomes, results, and assessors of quality was extracted.

Data Synthesis:

Five randomized controlled trials and 4 follow-up extension studies were identified. In Phase 2 trials, vaccine efficacy rates were 33–65% in infants and 30–53% in children for preventing the first episode of clinic a) disease. In Phase 3 trials, vaccine efficacy was 56% in children aged 5–17 months. RTS,S reduced (he number of clinical malaria episodes and prevented severe malaria in several studies. The follow-up period for vaccine efficacy ranged from 6 to 45 months. RTS,S 25 μg is administered intramuscularly as 3 injections given 1 month apart for infants and children. RTS,S appears to be generally well tolerated. A few cases of meningitis and seizures (within 7 days of vaccination) have been reported.

Conclusions:

RTS,S has demonstrated efficacy and safety in Phase 1, 2, and 3 trials, and has the potential to decrease morbidity and mortality from malaria worldwide. Major challenges include determination of the duration of immunity, assessment of its cost-effectiveness, its use in special populations, and its dissemination in endemic regions. Pending further studies, RTS,S has the potential to become the benchmark as the first effective vaccine against malaria.

Keywords

malaria pediatrics Plasmodium falciparum RTS,S vaccine

Get full access to this article

View all access options for this article.

References

World Health Organization. Factsheet on malaria, www.who.int/mediacentre/factsheets/fs094/en/ (accessed 19 Sept 2011).

Baird

. Effectiveness of antimalarial drugs. N Engl J Med 2005; 352:1565–77.

Casares

, Brumeanu

, Richie

. The RTS,S malaria vaccine. Vaccine 2010; 28:4880–94.

Sowunmi

. Hepatomegaly in acute falciparum malaria in children. T Roy Soc Trop Med H 1996; 90:540–2.

Jones

, Hoffman

. Malaria vaccine development. Clin Microbiol Rev 1994; 7:303–10.

GSK Biologicals, malaria vaccine initiative. Fact sheet RTS,S Malaria vaccine candidate. www.worldmalariaday.org/download/partners/Updated_RTSS_FactSheet_21_April_2010.pdf (accessed 19 Sept 2011).

Dame

, Williams

, McCutchan

. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984; 225: 593–9.

Ansong

, Asante

, Vekemans

. T cell responses to the RTS,S/AS01E and RTS,S/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS ONE 2011; 6:e18891.

Loucq

. The RTS,S/AS malaria vaccine candidate: results of phase 2 studies; design and status of the phase 3 trial, www.who.int/immunization/sage/20091028_MVI_SAGE_LOUCQ_FinalDraft.pdf (accessed 20 Sept 2011).

10.

Alonso

, Sacarlal

, Aponte

. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 2004; 364:1411–20.

11.

Bejon

, Lusingu

, Olotu

. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521–32.

12.

Abdulla

, Oberholzer

, Juma

. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008; 359:2533–44.

13.

Aponte

, Aide

, Renom

. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomized controlled phase I/IIb trial. Lancet 2007; 370:1543–51.

14.

Agnandji

, Lell

, Soulanoudjingar

. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863–75. DOI 10.1056/NEJMoa1102287

15.

Alonso

, Sacarlal

, Aponte

. Duration of protection with RTS,S/AS02A malaria vaccine in prevention ofPlasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized controlled trial. Lancet 2005; 366:2012–8.

16.

Sacarlal

, Aide

, Aponte

. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009; 200:329–36.

17.

Olotu

, Lusingu

, Leach

. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomized controlled trial. Lancet Infect Dis 2011; 11:102–9.

18.

Aide

, Aponte

, Renom

. Safety, immunogenicity and duration of protection of the RTS,S/AS02D malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS ONE 2010; 5:e13838.

19.

World Health Organization. Malaria: disease burden in SEA region. www.searo.who.int/en/Section10/Section21/Section340_4018.htm (accessed 7 Nov 2011).

20.

Polhemus

, Remich

, Ogutu

. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 2009; 4: e6465.

21.

Olotu

. RTS,S Phase III update, www.who.int/vaccine_research/documents/Session3_Olotu_presentation.pdf (accessed 6 Oct 2011).

22.

World Health Organization. Guidelines for the treatment of malaria. 2nd ed. http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf (accessed 10 Sept 2011).

23.

McGready

, White

, Nosten

. Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. BJOG 2011; 118:123–35.

24.

Levine

, Bloom

, Cherian

. The future of immunization policy, implementation, and financing. Lancet 2011; 378:439–48.